The letter notes that products were labeled for research use only or not for human consumption.
FDA posted the letter on September 1, 2026. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1
What does the letter say, in brief?
| Company | Royal Peptides LLC |
| Location | Boynton Beach, FL |
| Website named | royal-peptides.com |
| Letter dated | August 24, 2026 |
| Posted by FDA | September 1, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| FDA’s subject line | Unapproved New Drugs/Misbranded |
| Drugs named | semaglutide, tirzepatide and retatrutide |
| Kind of letter | Other |
| Reply asked within | No number of days stated |
| Close-out letter | None posted as of November 20, 2026 |
| FDA record | MARCS-CMS 734884 |
What did FDA quote?
The letter quotes 12 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1
Tirzepatide has become a major focus of metabolic, endocrinology, obesity, and peptide science due to its unique activity at both the GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors.
Tirzepatide is a synthetic peptide engineered to activate both the GIP receptor and GLP-1 receptor, making it the first widely researched dual incretin agonist. Unlike traditional GLP-1 receptor agonists that target only one metabolic pathway, Tirzepatide simultaneously stimulates two naturally occurring incretin systems involved in glucose regulation and metabolic signaling.
Benefits of Tirzepatide: Enhances insulin sensitivity and glucose control[,] Reduces appetite and cravings[,] Promotes sustainable weight loss[, and] Once-weekly injection for convenience Clinical Results for Weight Loss In studies, Tirzepatide has led to up to 22.5% body weight reduction in participants over 72 weeks—comparable to or even better than Semaglutide (Wegovy, Ozempic).
Benefits of Retatrutide: Boosts metabolism by activating glucagon receptors[,] Enhances glucose control and insulin function[,] Leads to faster and more substantial weight loss than Tirzepatide[, and] Once-weekly dosing Clinical Results for Weight Loss Early trials suggest that Retatrutide may result in up to 24.2% body weight reduction in just 48 weeks, making it one of the most effective weight loss peptides currently being studied.
Unlock dual research potential with Royal Peptides’ Mix 10-Pack Kit, combining 5 vials of Tirzepatide 10mg and 5 vials of Retatrutide 10mg—two powerhouse GLP-1/GIP receptor agonists studied for their roles in metabolic and weight management research.
Researchers studying incretin biology have long investigated the effects of GLP-1 and GIP receptor activity. Retatrutide expands on this concept by incorporating glucagon receptor activity into the molecule’s design. This additional receptor interaction has created widespread interest among scientists studying metabolic regulation and energy balance.
Semaglutide Single Vials is categorized under metabolic signaling research. It may be examined in research involving metabolic signaling, receptor selectivity and related biochemical pathways.
SS-31 (Elamipretide) is a breakthrough mitochondria-targeted tetrapeptide researched for its potential in reducing oxidative stress, enhancing cellular energy production, and supporting mitochondrial function.
4 more quotes are in the full letter below.
Which parts of the law did FDA cite?
The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.
| Section | What it says | Letters citing it |
|---|---|---|
| 505(a) | A new drug may not be sold across state lines without an approved application | 48 |
| 301(d) | It is prohibited to introduce a drug into interstate commerce in violation of section 505 | 48 |
What did FDA ask the company to do?
FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1
Has FDA warned the seller I use?
Type a seller’s name or website. The search runs over all 164 letters in this database.
How many GLP-1 letters has FDA sent?
16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 115 of the 164 letters name tirzepatide. 21 of the 164 letters name retatrutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.
Which other sellers got a similar letter?
What does an FDA warning letter mean for someone buying from this seller?
FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.
FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.
A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.
What is the full text of the letter?
This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1
Read the full letter (1430 words)
Reference Number: 734884
To Rocco Abate and Michael Fraunfelter:
This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.
These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.
FDA Review
Violations were identified and documented during a review of your website royal-peptides.com in July 2026. Based on our review, “Tirzepatide,” “Semaglutide,” “Retatrutide,” “SS-31 (Elamipretide),” “PT-141,” “Tesamorelin,” and “BIMORELIN” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.
Violations of the Federal Food, Drug, and Cosmetic Act
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.
Unapproved New Drug Violations
Based on a review of your website, “Tirzepatide,” “Semaglutide,” “Retatrutide,” “SS-31 (Elamipretide),” “PT-141,” “Tesamorelin,” and “BIMORELIN” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.1 Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:
Tirzepatide, Retatrutide, and Semaglutide
On the webpage https://royal-peptides.com/shop/tirzepatide-vials/:
“Tirzepatide has become a major focus of metabolic, endocrinology, obesity, and peptide science due to its unique activity at both the GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors.”
“Tirzepatide is a synthetic peptide engineered to activate both the GIP receptor and GLP-1 receptor, making it the first widely researched dual incretin agonist. Unlike traditional GLP-1 receptor agonists that target only one metabolic pathway, Tirzepatide simultaneously stimulates two naturally occurring incretin systems involved in glucose regulation and metabolic signaling.”
On the webpage http://royal-peptides.com/tirzepatide-vs-retatrutide-weight-loss-peptides/:
“Benefits of Tirzepatide: Enhances insulin sensitivity and glucose control[,] Reduces appetite and cravings[,] Promotes sustainable weight loss[, and] Once-weekly injection for convenience
Clinical Results for Weight Loss
In studies, Tirzepatide has led to up to 22.5% body weight reduction in participants over 72 weeks—comparable to or even better than Semaglutide (Wegovy, Ozempic).”
“Benefits of Retatrutide: Boosts metabolism by activating glucagon receptors[,] Enhances glucose control and insulin function[,] Leads to faster and more substantial weight loss than Tirzepatide[, and] Once-weekly dosing
Clinical Results for Weight Loss
Early trials suggest that Retatrutide may result in up to 24.2% body weight reduction in just 48 weeks, making it one of the most effective weight loss peptides currently being studied.”
On the webpage https://royal-peptides.com/retatrutide-vs-tirzepatide/:
“One of the main reasons Retatrutide is searched so heavily is its connection to body composition research. Tirzepatide already became a major comparison point in metabolic studies because of its dual GIP and GLP-1 receptor activity. Retatrutide builds on that research conversation by adding glucagon receptor activity.
Retatrutide Research Interest
Retatrutide is studied for how triple agonist activity may influence metabolic research models. The addition of glucagon receptor activity is especially important because glucagon is involved in energy balance and hepatic glucose output. This makes Retatrutide interesting in models where researchers are examining energy expenditure, body composition, and metabolic regulation.”
On the webpage https://royal-peptides.com/shop/tirzepatide-retatrutide-10mg-mix-kit-55-pack/:
“Unlock dual research potential with Royal Peptides’ Mix 10-Pack Kit, combining 5 vials of Tirzepatide 10mg and 5 vials of Retatrutide 10mg—two powerhouse GLP-1/GIP receptor agonists studied for their roles in metabolic and weight management research.”
On the webpage https://royal-peptides.com/shop/retatrutide-vial/:
“Researchers studying incretin biology have long investigated the effects of GLP-1 and GIP receptor activity. Retatrutide expands on this concept by incorporating glucagon receptor activity into the molecule’s design. This additional receptor interaction has created widespread interest among scientists studying metabolic regulation and energy balance.”
On the webpage https://royal-peptides.com/shop/semaglutide/:
“Semaglutide Single Vials is categorized under metabolic signaling research. It may be examined in research involving metabolic signaling, receptor selectivity and related biochemical pathways.”
SS-31 (Elamipretide)
On the webpage https://royal-peptides.com/shop/31pv/:
“SS-31 (Elamipretide) is a breakthrough mitochondria-targeted tetrapeptide researched for its potential in reducing oxidative stress, enhancing cellular energy production, and supporting mitochondrial function.”
“Advanced Research Use: Mitochondrial repair, anti-aging, neuroprotection”
Tesamorelin and BIMORELIN
On the webpage https://royal-peptides.com/shop/tesamorelin-10mg/:
“Tesamorelin is categorized under growth-signaling research. It may be examined in research involving peptide signaling, endocrine pathways and growth-hormone-related mechanisms.”
On the webpage https://royal-peptides.com/shop/tesamorelin-ipamorelin-blend/:
“BIMORELIN is a cutting-edge dual peptide blend combining Tesamorelin (10mg) and Ipamorelin (3mg) for advanced research into hormone modulation, body composition, and cellular recovery.”
“Tesamorelin and Ipamorelin are synthetic peptides frequently utilized in scientific research involving cellular communication, metabolic regulation, recovery pathways, tissue maintenance, and physiological performance studies. When combined, researchers can investigate potential complementary effects across multiple biological systems and signaling networks.”
PT-141
On the webpage https://royal-peptides.com/shop/pt-141-10mg-vial/:
“PT-141, also called Bremelanotide (generic clinical name), is a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for hypoactive sexual desire disorder and acute hemorrhage.”
“Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction”
“PT-141: a melanocortin agonist for the treatment of sexual dysfunction”
“Tirzepatide,” “Semaglutide,” “Retatrutide,” “SS-31 (Elamipretide),” “PT-141,” “Tesamorelin,” and “BIMORELIN” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Conclusion
As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “734884” in the subject line of the email.
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
Please note FDA posts warning letters on www.fda.gov.
Sincerely,
/S/
Tina Smith, M.S.
Captain, U.S. Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
________________________
1 Despite statements on your product labeling marketing your products “for research use only” and “not for human or animal consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a “peptide guide” and “peptide calculator,” resources that collectively provide the means to prepare an injectable drug for human administration.
Content current as of:
09/01/2026
Regulated Product(s)
Drugs
Sources
- FDA. Warning letter to Royal Peptides LLC, August 24, 2026 (MARCS-CMS 734884). fda.gov
- FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
- FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider